{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:52:18Z","timestamp":1793026338698,"version":"4.5.0"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Retention on methadone and buprenorphine has been shown to be associated with reduced overdose and death. Opioid treatment programs (OTPs) are the only health care facilities in the US licensed to dispense methadone for opioid use disorder (OUD), and they increasingly prescribe buprenorphine. By measuring and comparing their patient retention rates, after adjusting for patient characteristics, OTPs can determine if their retention rate is low relative to other OTPs, which may motivate efforts to improve patient engagement and outcomes.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To develop a standardized case mix\u2013adjusted measure for evaluating Medicaid patient retention in OTPs.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used Medicaid outpatient claims and demographic data from 2018 to 2023. All OTPs in the US with at least 11 non\u2013dually eligible Medicaid beneficiaries aged 18 years or older with an OUD diagnosis were included. Analyses were completed between January and October 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n OUD treatment at OTPs.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The percentage of an OTP\u2019s Medicaid patients who remained in treatment at the OTP for greater than 30 days, greater than 90 days, and greater than 180 days. Retention rates were calculated for 5 measurement years (2019 through 2023; eg, July 1, 2018, to June 30, 2019) and underwent case mix adjustment using Medicaid data and patient characteristics.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study included 261\u202f025 Medicaid beneficiaries (140\u202f718 males [53.9%]; mean [SD] age, 39 [9.92] years) with 432\u202f918 episodes of treatment at 1138 OTPs in measurement year 2023. The median (IQR) 30-day, 90-day, and 180-day retention rates were 61.2% (40.9%-73.5%), 41.5% (22.2%-54.8%), and 27.5% (11.4%-40.5%), respectively, in measurement year 2023.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This cohort study found low retention rates and variable treatment duration across OTPs. This result indicates opportunities for quality improvement.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.53538","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:30:32Z","timestamp":1769185832000},"page":"e2553538","source":"Crossref","is-referenced-by-count":6,"title":["Opioid Treatment Programs\u2019 Medicaid Patient Retention Rates"],"prefix":"10.1001","volume":"9","author":[{"given":"Dylan E.","family":"DeLisle","sequence":"first","affiliation":[{"name":"RTI International, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami L.","family":"Mark","sequence":"additional","affiliation":[{"name":"RTI International, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Katz","sequence":"additional","affiliation":[{"name":"RTI International, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William N.","family":"Dowd","sequence":"additional","affiliation":[{"name":"RTI International, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Barch","sequence":"additional","affiliation":[{"name":"RTI International, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Kluckman","sequence":"additional","affiliation":[{"name":"RTI International, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"9","key":"zoi251426r2","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"12","key":"zoi251426r3","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis.","volume":"24","author":"Ma","year":"2019","journal-title":"Mol Psychiatry"},{"key":"zoi251426r4","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"zoi251426r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/ADM.0000000000000633","article-title":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 focused update.","volume":"14","year":"2020","journal-title":"J Addict Med"},{"issue":"1","key":"zoi251426r6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: a systematic review.","volume":"35","author":"Timko","year":"2016","journal-title":"J Addict Dis"},{"issue":"4","key":"zoi251426r7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1037\/0893-164X.11.4.279","article-title":"Program diversity and treatment retention rates in the Drug Abuse Treatment Outcome Study (DATOS).","volume":"11","author":"Simpson","year":"1997","journal-title":"Psychol Addict Behav"},{"issue":"1","key":"zoi251426r8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF02287327","article-title":"Retention in publicly funded methadone maintenance treatment in two Western States.","volume":"32","author":"Deck","year":"2005","journal-title":"J Behav Health Serv Res"},{"issue":"5","key":"zoi251426r9","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/j.1360-0443.2009.02538.x","article-title":"Retention in methadone maintenance drug treatment for prescription-type opioid primary users compared to heroin users.","volume":"104","author":"Banta-Green","year":"2009","journal-title":"Addiction"},{"issue":"5","key":"zoi251426r10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1360-0443.2011.03700.x","article-title":"Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings.","volume":"107","author":"Schwartz","year":"2012","journal-title":"Addiction"},{"issue":"4","key":"zoi251426r11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1037\/adb0000090","article-title":"Predictors of patient retention in methadone maintenance treatment.","volume":"29","author":"Proctor","year":"2015","journal-title":"Psychol Addict Behav"},{"issue":"6","key":"zoi251426r12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000259.pub3","article-title":"Audit and feedback: effects on professional practice and healthcare outcomes.","volume":"2012","author":"Ivers","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi251426r13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000259.pub2","article-title":"Audit and feedback: effects on professional practice and health care outcomes.","author":"Jamtvedt","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"zoi251426r16","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.4365","article-title":"Drug overdose deaths among Medicaid beneficiaries.","volume":"5","author":"Mark","year":"2024","journal-title":"JAMA Health Forum"},{"issue":"5","key":"zoi251426r17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232086","article-title":"Retention of patients in opioid substitution treatment: a systematic review.","volume":"15","author":"O\u2019Connor","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"zoi251426r18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"1","key":"zoi251426r20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12954-022-00592-x","article-title":"Interim opioid agonist treatment for opioid addiction: a systematic review.","volume":"19","author":"Sams\u00f3 Jofra","year":"2022","journal-title":"Harm Reduct J"},{"issue":"3","key":"zoi251426r21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002208","article-title":"Methadone maintenance at different dosages for opioid dependence.","author":"Faggiano","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"zoi251426r22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/BF02521117","article-title":"Measuring program performance in methadone treatment using in-treatment outcomes: an illustration.","volume":"22","author":"Phillips","year":"1995","journal-title":"J Ment Health Adm"},{"issue":"1","key":"zoi251426r23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/01632780022034499","article-title":"Implementation of the methadone treatment quality assurance system. Findings from the feasibility study.","volume":"23","author":"Ducharme","year":"2000","journal-title":"Eval Health Prof"},{"key":"zoi251426r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2022.108824","article-title":"Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.","volume":"140","author":"Dowd","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"zoi251426r25","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1176\/appi.ps.202000879","article-title":"Development, testing, and dissemination of a public-facing tool to help consumers find higher-quality addiction treatment.","volume":"73","author":"Mark","year":"2022","journal-title":"Psychiatr Serv"},{"key":"zoi251426r1","unstructured":"U.S. overdose deaths decrease almost 27% in 2024. National Center for Health Statistics. May 9, 2025. Accessed July 16, 2025. https:\/\/www.cdc.gov\/nchs\/pressroom\/releases\/20250514.html"},{"key":"zoi251426r14","unstructured":"Research Data Assistance Center (ResDAC). Accessed July 16, 2025. https:\/\/resdac.org\/"},{"key":"zoi251426r15","unstructured":"Treatment Episode Data Set\u2013Discharges (TEDS-D), 2022. CBHSQ data. Substance Abuse and Mental Health Services Administration. Accessed July 16, 2025. https:\/\/www.samhsa.gov\/data\/dataset\/teds-d-2022-ds0001-teds-d-2022-ds0001"},{"key":"zoi251426r19","doi-asserted-by":"crossref","unstructured":"Adams? JL. The reliability of provider profiling: a tutorial. RAND Corporation. June 25, 2009. Accessed July 16, 2025. https:\/\/www.rand.org\/pubs\/technical_reports\/TR653.html.","DOI":"10.7249\/TR653"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2844211\/delisle_2026_oi_251426_1768499058.94029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T16:30:36Z","timestamp":1769185836000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2844211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.53538","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}